Indo American Journal of Pharmaceutical Research

ISSN NO.: 2231-6876
JUNE 2019


K.Yogendra*, S. Rajini, V.Mohana, G.V.Chari, P.Supraja, M.Prasada Rao
M.A.M College of Pharmacy, Narsaraopeta, Guntur District, A.P.

Introduction: Quality of Life assessment has become increasingly common in the field of cancer and has been identified as the second most important outcome with survival being the most important. For patients and their family, a diagnosis of cancer brings challenges to many aspects of daily life, with a major concern being maintaining the highest quality of life possible during and after the experience. This study was carried out with the objective of measuring the quality of life of pediatric leukemic patients during their cancer treatment. Materials and Methodology: The data required for the study was collected from the patients at Primary Healthcare Hospital. The data is collected from Leukemic pediatric patients who were in the Oncology department. The Quality of Life was measured by using PedsQL, A prominent Quality assessing scale for pediatrics. The data was computed from the patient data collection forms. Data pertaining to physical functioning, emotional functioning, social functioning, school functioning characteristics of patients was stockpiled. Results: Physical Functioning ( P > 0.05), Emotional Functioning ( P > 0.05), Social Functioning ( P > 0.05), School functioning ( P > 0.05). The significance (2 tailed) values Emotional Functioning implicate that most of the patients have angry. The significance (2 tailed) values Social Functioning implicate that most of the patients getting teased by other children. The significance (2 tailed) values School Functioning implicate that most of the patients have problems with paying attention in classs, keeping up with school work, missing school because of not feeling well, missing school to go to doctor or hospital. Conclusion: Anxiety, irritability, worries, depression, and aggression were also sometimes a barrier to communicate with the patients and for them to complete the questionnaire. It should be noted that the approximate time to enter the study for this number of subjects (n = 49) was 3 months. Another limitation was the limited environment of the study; due to this limitation, studying patients with leukemia admitted in other hospitals at the same time was not possible. Based on the limitations of this study, including the small number of subjects, applying the study only in one hospital, and in only one section, and the problems of generalizability, it is recommended for further similar studies to be conducted in other hospitals with larger sample size. 




Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal
Kasturi Shikshan Sanstha’s College of Pharmacy, Shikrapur, Pune-412207, Maharashtra, India.

Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples. In short use of biomarker data will help us make the best possible use of precious human samples and maximize the chances of success of the most promising therapeutic approaches. 




Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal
Kasturi Shikshan Sanstha’s College of Pharmacy, Shikrapur, Pune-412207, Maharashtra, India.

In recent days many women’s affected by breast cancer. Years between 1990 to 2014 rates of breast cancer dropped by 34 % in the US attributable to the combination of effective adjuvant therapies & improving in the earlier detection. In low & middle income countries breast cancer is increasingly problems. Historically it is observed that low incidence rates have been rising per year up to the 5%. Breast cancer cause due to various social causes also that is hormonal changes, Life style, weight. Stem cell have also important role in breast cancer. Because of these various reasons there is need to aware about breast cancer. In present study we tried to explain causes of breast cancer so we can easily understand that breast cancer is serious challenge that we have to carry and need to find out proper and cheap treatment on same. 




Bharath G.J*, Yogananda R, Nagaraja T.S, Vitthal K Vijapure, Bharathi D.R
SJM College of Pharmacy SJM Campus, Chitradurga, Karnataka, India.

In the present study an attempt was made to prepare and evaluate nanoparticles containing pitavastatin by sonication method. The prepared formulations were characterized by scanning electron microscopy, Fourier transforms infrared spectroscopy, differential scanning calorimetry, X-ray diffraction, nanoparticle prepared were subjected for Particle size, entrapment efficiency, in-vitro drug release. The prepared Nanoparticles are spherical and smooth in surface. The size of nanoparticles 978.85 nm and drug entrapment efficiency was in the range of 80.26% to 95.39 %. The DSC analysis and X-ray diffraction studies indicated that the drug was uniformly dispersed in an amorphous state in the formulation. The in-vitro drug release studies indicated nanoparticles containing pitvastatin prepared by probe sonication methods shows good release rate but formulation Pt9 shows retard drug release from nanoparticles because combination of PMMA & HPC helps to release drug slowly for 24 hours. Results indicated that prepared formulation were intact up to 8 hours. Drug released mechanism follows the Non-Fickian transport. The stability test of optimized formulations are carried out according to ICH guideline, which shown that the formulations were stable in temperature condition. By the use of biocompatible and cost effective polymers like PMMA and HPC we can formulate Nano particulate drug delivery of Pitavastatin in controlled manner with good entrapment efficiency. 




Ware Agasti L.*, Pekamwar S.S.
1Sanjivani College of Pharmaceutical Education and Research, Kopargaon.
2Swami Ramanand Teerth Marathwada University, Nanded.

Impurity profiling is the process of acquiring and evaluating data that establishes biological safety of an individual impurity. There is no clear definition for impurity in the pharmaceutical world. Impurity profiling includes identification, structure elucidation and quantitative determination of impurities and degradation products in bulk drug materials and pharmaceutical formulations. Impurity profiling has gained importance in modern pharmaceutical analysis due to the fact that unidentified, potentially toxic impurities are hazardous to health and in order to increase the safety of drug therapy, impurities should be identified and determined by selective methods. Identification of impurities is done by variety of Chromatographic and Spectroscopic techniques, either alone or in combination with other techniques. The advent of hyphenated techniques has revolutionized impurity profiling, by not only separation but structural identification of impurities as well. The present review covers various aspects related to the analytical method development for impurity profiling of an active pharmaceuticals. Impurity profiling encounters problems in bulk drugs since it assists in enhancing bulk drug quality ultimately benefiting patient. 




Ware Agasti L.*, Pekamwar S.S.1
1Sanjivani College of Pharmaceutical Education and Research, Kopargaon
2Swami Ramanand Teerth Marathwada University, Nanded.

The identification, characterization and control of both the processes and degradation related impurities in Active Pharmaceutical Ingredients (APIs) or drug substances are the essential aspects of drug development2,3,4. Complete elimination of impurities for safe human consumption has been the goal of both pharmaceutical companies and various regulatory agencies1. Consequently, for any drug registration, one of the principal requirements is to specify both identified and unidentified impurities in drug substance/drug product as per ICH guidelines Q3A(R), Q3B(R) and Q3C [1]6. Characterization of impurities is required, particularly when they are present at a level higher than the identification threshold to control their levels in the final API or drug product1,6.